Vasoactive intracavernous pharmacotherapy for the treatment of erectile impotence in men with spinal cord injury

A. A. Sidi, J. S. Cameron, D. D. Dykstra, Y. Reinberg, P. H. Lange

Research output: Contribution to journalArticlepeer-review

Abstract

A total of 66 spinal cord injury patients with erectile dysfunction entered a protocol of penile intracavernous pharmacotherapy with papaverine hydrochloride (30 mg. per ml.) or a combination of papaverine (25 mg. per ml.) and phentolamine mesylate (0.83 mg. per ml.) in an attempt to restore erectile function. Of the patients 52 completed the protocol and all achieved transient functional penile erections after administration of the drug. Of the 52 responders 71 per cent currently practice self-injection as a method to restore erectile function. Sustained erections that required irrigation of the cavernous bodies with alpha-adrenergic agents developed in 4 patients and 1 suffered localized intracorporeal induration. If the long-term followup shows that complications remain relatively minor, undoubtedly vasoactive intracavernous pharmacotherapy will have a major role in the restoration of erectile function in the motivated man with spinal cord injury. However, in view of the unknown long-term effects and potential dangers of this approach it is important that patients adhere to a strict drug injection protocol under the supervision of qualified urologists who are familiar with the potential risks and complications.

Original languageEnglish
Pages (from-to)539-542
Number of pages4
JournalJournal of Urology
Volume138
Issue number3
DOIs
StatePublished - 1987

Fingerprint

Dive into the research topics of 'Vasoactive intracavernous pharmacotherapy for the treatment of erectile impotence in men with spinal cord injury'. Together they form a unique fingerprint.

Cite this